New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease
A series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds <b>3a</b>, <b>3b</b>, <b>3f</b>, and <b>3g</b>...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/11/3765 |
id |
doaj-e31425d6c23c4996a96f2fb20d8acfc8 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kamila Czarnecka Małgorzata Girek Przemysław Wójtowicz Paweł Kręcisz Robert Skibiński Jakub Jończyk Kamil Łątka Marek Bajda Anna Walczak Grzegorz Galita Jacek Kabziński Ireneusz Majsterek Piotr Szymczyk Paweł Szymański |
spellingShingle |
Kamila Czarnecka Małgorzata Girek Przemysław Wójtowicz Paweł Kręcisz Robert Skibiński Jakub Jończyk Kamil Łątka Marek Bajda Anna Walczak Grzegorz Galita Jacek Kabziński Ireneusz Majsterek Piotr Szymczyk Paweł Szymański New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease International Journal of Molecular Sciences acetylcholinesterase inhibitors Alzheimer’s disease molecular modeling Ellman’s method |
author_facet |
Kamila Czarnecka Małgorzata Girek Przemysław Wójtowicz Paweł Kręcisz Robert Skibiński Jakub Jończyk Kamil Łątka Marek Bajda Anna Walczak Grzegorz Galita Jacek Kabziński Ireneusz Majsterek Piotr Szymczyk Paweł Szymański |
author_sort |
Kamila Czarnecka |
title |
New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease |
title_short |
New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease |
title_full |
New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease |
title_fullStr |
New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease |
title_full_unstemmed |
New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s Disease |
title_sort |
new tetrahydroacridine hybrids with dichlorobenzoic acid moiety demonstrating multifunctional potential for the treatment of alzheimer’s disease |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-05-01 |
description |
A series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds <b>3a</b>, <b>3b</b>, <b>3f</b>, and <b>3g</b> exhibited selective butyrylcholinesterase (<i>Eq</i>BuChE) inhibition with IC<sub>50</sub> values ranging from 24 to 607 nM. Among them, compound 3b was the most active (IC<sub>50</sub> = 24 nM). Additionally, 3c (IC<sub>50</sub> for <i>Ee</i>AChE = 25 nM and IC<sub>50</sub> for <i>Eq</i>BuChE = 123 nM) displayed dual cholinesterase inhibitory activity and was the most active compound against acetylcholinesterase (AChE). Active compound 3c was also tested for the ability to inhibit Aβ aggregation. Theoretical physicochemical properties of the compounds were calculated using ACD Labs Percepta and Chemaxon. A Lineweaver–Burk plot and docking study showed that 3c targeted both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. Moreover, 3c appears to possess neuroprotective activity and could be considered a free-radical scavenger. In addition, 3c did not cause DNA damage and was found to be less toxic than tacrine after oral administration; it also demonstrated little inhibitory activity towards hyaluronidase (HYAL), which may indicate that it possesses anti-inflammatory properties. The screening for new in vivo interactions between 3c and known receptors was realized by yeast three-hybrid technology (Y3H). |
topic |
acetylcholinesterase inhibitors Alzheimer’s disease molecular modeling Ellman’s method |
url |
https://www.mdpi.com/1422-0067/21/11/3765 |
work_keys_str_mv |
AT kamilaczarnecka newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT małgorzatagirek newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT przemysławwojtowicz newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT pawełkrecisz newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT robertskibinski newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT jakubjonczyk newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT kamilłatka newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT marekbajda newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT annawalczak newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT grzegorzgalita newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT jacekkabzinski newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT ireneuszmajsterek newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT piotrszymczyk newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease AT pawełszymanski newtetrahydroacridinehybridswithdichlorobenzoicacidmoietydemonstratingmultifunctionalpotentialforthetreatmentofalzheimersdisease |
_version_ |
1724699728201908224 |
spelling |
doaj-e31425d6c23c4996a96f2fb20d8acfc82020-11-25T03:00:02ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-05-01213765376510.3390/ijms21113765New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer’s DiseaseKamila Czarnecka0Małgorzata Girek1Przemysław Wójtowicz2Paweł Kręcisz3Robert Skibiński4Jakub Jończyk5Kamil Łątka6Marek Bajda7Anna Walczak8Grzegorz Galita9Jacek Kabziński10Ireneusz Majsterek11Piotr Szymczyk12Paweł Szymański13Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, PolandDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, PolandDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, PolandA series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds <b>3a</b>, <b>3b</b>, <b>3f</b>, and <b>3g</b> exhibited selective butyrylcholinesterase (<i>Eq</i>BuChE) inhibition with IC<sub>50</sub> values ranging from 24 to 607 nM. Among them, compound 3b was the most active (IC<sub>50</sub> = 24 nM). Additionally, 3c (IC<sub>50</sub> for <i>Ee</i>AChE = 25 nM and IC<sub>50</sub> for <i>Eq</i>BuChE = 123 nM) displayed dual cholinesterase inhibitory activity and was the most active compound against acetylcholinesterase (AChE). Active compound 3c was also tested for the ability to inhibit Aβ aggregation. Theoretical physicochemical properties of the compounds were calculated using ACD Labs Percepta and Chemaxon. A Lineweaver–Burk plot and docking study showed that 3c targeted both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. Moreover, 3c appears to possess neuroprotective activity and could be considered a free-radical scavenger. In addition, 3c did not cause DNA damage and was found to be less toxic than tacrine after oral administration; it also demonstrated little inhibitory activity towards hyaluronidase (HYAL), which may indicate that it possesses anti-inflammatory properties. The screening for new in vivo interactions between 3c and known receptors was realized by yeast three-hybrid technology (Y3H).https://www.mdpi.com/1422-0067/21/11/3765acetylcholinesterase inhibitorsAlzheimer’s diseasemolecular modelingEllman’s method |